Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI8897 vs Palivizumab for RSV in High-risk Children
NCT03959488Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Primary completion
- May 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of nirsevimab in respiratory syncytial virus infection (RSV), sponsored by AstraZeneca. Started Jul 2019; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03959488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959488.